135 related articles for article (PubMed ID: 9690943)
21. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
22. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.
Stadler WM; Rybak ME; Vogelzang NJ
Cancer; 1995 Nov; 76(9):1629-33. PubMed ID: 8635068
[TBL] [Abstract][Full Text] [Related]
25. alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.
Atzpodien J; Poliwoda H; Kirchner H
Semin Oncol; 1991 Oct; 18(5 Suppl 7):108-12. PubMed ID: 1948123
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study.
Huland E; Burger A; Fleischer J; Fornara P; Hatzmann E; Heidenreich A; Heinzer H; Heynemann H; Hoffmann L; Hofmann R; Huland H; Kämpfer I; Kindler M; Kirchner H; Mehlhorn G; Moniak TH; Rebmann U; Roigas J; Schneider TH; Schnorr D; Schmitz HJ; Wenisch R; Varga Z; Vinke J
Folia Biol (Praha); 2003; 49(5):183-90. PubMed ID: 14680292
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys.
Li R; Deng F; Fu Y; Zhang Y; Wan H; Zhou D; Gu J; Xu J
Pharmacology; 2010; 85(6):319-27. PubMed ID: 20516733
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.
Middleton M; Sarno M; Agarwala SS; Glaspy J; Laurent A; McMasters K; Naredi P; O'Day S; Whitman E; Danson S; Cosford R; Gehlsen K
J Clin Pharmacol; 2002 Jul; 42(7):774-81. PubMed ID: 12092744
[TBL] [Abstract][Full Text] [Related]
31. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancer.
Schiphorst PP; Chang PC; Clar N; Schoemaker RC; Osanto S
Ann Oncol; 1999 Nov; 10(11):1381-3. PubMed ID: 10631470
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Andres M; Scardino E; Tancini G
Oncology; 1994; 51(1):59-62. PubMed ID: 8265104
[TBL] [Abstract][Full Text] [Related]
36. [Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma].
Lissoni P; Barni S; Tancini G; Cazzaniga M; Frigerio F; Chilelli M; Scardino E; Andres M; Favini P; Meroni T; Verwei F; Baccalin A; Sala M; Frea B; Kocjancic E; Rocco F
Arch Ital Urol Androl; 1997 Feb; 69(1):41-7. PubMed ID: 9181905
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma.
Lümmen G; Goepel M; Möllhoff S; Hinke A; Otto T; Rübben H
J Urol; 1996 Feb; 155(2):455-8. PubMed ID: 8558634
[TBL] [Abstract][Full Text] [Related]
39. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
[TBL] [Abstract][Full Text] [Related]
40. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.
Figlin RA; Thompson JA; Bukowski RM; Vogelzang NJ; Novick AC; Lange P; Steinberg GD; Belldegrun AS
J Clin Oncol; 1999 Aug; 17(8):2521-9. PubMed ID: 10561318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]